Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Language Learning Stages: Which One Gets Your Vote? - 2Yoshi mania, Happy Meals and not-so-great reviews: A small talk guide to 'The Super Mario Galaxy Movie'
- 3France bans Muslim gathering citing risk to participants
- 4Grasping Various Kinds of Local misdemeanors
- 5The best overlooked performances of 2025
- Make your choice for the music application with the most amicable connection point!
- Shredded cheese sold in dozens of states recalled due to potential for metal fragment contamination
- Cases of norovirus are on the rise just in time for the holiday season
- Pfizer says patient dies after receiving hemophilia drug in trial
- AI is making spacecraft propulsion more efficient – and could even lead to nuclear-powered rockets
- 80 km. on foot: Sharren Haskel’s three-day march in protest of haredi draft bill
- 7 Heavenly Espressos, One Do You Like?
- Research highlights potential dangers of ultra-processed foods for women under 50 regarding precancerous polyps
- Iranian naval commander Alireza Tangsiri killed in attack, says Israel
